Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

J. A. Johnson, L. Gong, M. Whirl-Carrillo, B. F. Gage, S. A. Scott, C. M. Stein, J. L. Anderson, S. E. Kimmel, M. T.M. Lee, M. Pirmohamed, M. Wadelius, T. E. Klein, R. B. Altman

Research output: Contribution to journalReview articlepeer-review

477 Scopus citations

Abstract

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ∼50% of warfarin dose variability. The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www.pharmgkb. org based on new developments in the field. 1.

Original languageEnglish
Pages (from-to)625-629
Number of pages5
JournalClinical pharmacology and therapeutics
Volume90
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Dive into the research topics of 'Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing'. Together they form a unique fingerprint.

Cite this